Nordea Investment Management AB Purchases 16,616 Shares of Charles River Laboratories International, Inc. $CRL

Nordea Investment Management AB increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 43.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 54,694 shares of the medical research company’s stock after acquiring an additional 16,616 shares during the quarter. Nordea Investment Management AB’s holdings in Charles River Laboratories International were worth $10,985,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Procyon Advisors LLC purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth approximately $236,000. Everhart Financial Group Inc. increased its holdings in Charles River Laboratories International by 37.9% during the fourth quarter. Everhart Financial Group Inc. now owns 2,634 shares of the medical research company’s stock valued at $525,000 after buying an additional 724 shares during the period. Confluence Investment Management LLC increased its holdings in Charles River Laboratories International by 10.1% during the fourth quarter. Confluence Investment Management LLC now owns 105,626 shares of the medical research company’s stock valued at $21,070,000 after buying an additional 9,663 shares during the period. Park Avenue Securities LLC raised its stake in Charles River Laboratories International by 6.1% in the fourth quarter. Park Avenue Securities LLC now owns 2,057 shares of the medical research company’s stock worth $410,000 after buying an additional 118 shares in the last quarter. Finally, Miller Global Investments LLC purchased a new stake in Charles River Laboratories International during the fourth quarter worth $422,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL opened at $165.70 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. The company’s fifty day moving average price is $181.98 and its 200-day moving average price is $180.65. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $228.88. The firm has a market capitalization of $8.16 billion, a PE ratio of -55.98, a price-to-earnings-growth ratio of 2.72 and a beta of 1.64.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The company had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. During the same quarter last year, the business posted $2.66 EPS. The firm’s quarterly revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a research note on Monday, December 15th. Evercore raised their price objective on Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. JPMorgan Chase & Co. boosted their target price on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a report on Monday, December 15th. Finally, Robert W. Baird set a $193.00 price target on shares of Charles River Laboratories International in a research report on Thursday, February 19th. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $206.15.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.